Carcinomas of the extrahepatic bile ducts are uncommon neoplasms that are morphologically heterogeneous and associated with a poor prognosis. We have previously shown that the noninvasive and minimally invasive papillary carcinomas of the extrahepatic bile ducts behave as in situ carcinomas and are associated with a better prognosis. We reviewed the clinical records of 13 patients with invasive papillary carcinomas of the extrahepatic bile ducts and analyzed the microscopic features and selected immunohistochemical reactivity (p53, Mib-1, and Dpc4) that might correlate with patient survival. In addition, we present the updated SEER (Surveillance, Epidemiology, and End Results) data of the National Cancer Institute for the invasive extrahepatic bile duct carcinomas compiled from 1975 to 1998. The 13 patients with papillary carcinoma had a male to female ratio of 1:1, and their ages ranged from 33 to 89 years. Painless jaundice and abdominal pain were the most common complaints. Five tumors were located in the distal portion, one in the mid portion, and six in the proximal portion of the common bile duct. One papillary carcinoma arose in the right hepatic duct. The Whipple procedure was performed in six patients, common bile duct resection in six, and right hepatic lobectomy in one. The cell phenotype of the papillary carcinomas was biliary in nine and intestinal in three. One tumor had both biliary and intestinal phenotypes. Four tumors dedifferentiated (two to undifferentiated small cell carcinomas, one to small
79 cases of papillary carcinomas (6%; 2). Papillary carcinomas appear to have better prognosis than do other types of carcinoma of the extrahepatic bile ducts (2) . This relatively good prognosis of papillary carcinomas is attributed to the exophytic nature of the tumors, their late invasion into the ductal wall, and their location. The exophytic nature of papillary carcinomas gives rise to obstructive symptoms sooner than in the case of conventional adenocarcinomas. In addition, tumors located in the distal third of the common bile duct can be resected by means of a pancreatoduodenectomy.
We have shown elsewhere that the noninvasive and minimally invasive papillary carcinomas of the extrahepatic bile ducts behave as in situ carcinomas and are associated with a better prognosis (3) . In this study, we examined the clinical, morphologic, and immunohistochemical features of 13 papillary carcinomas of the extrahepatic bile ducts that invaded the full thickness of the wall or extended beyond the ductal wall. In addition, we present the updated SEER data for the invasive extrahepatic bile duct carcinomas compiled from 1975 to 1998.
MATERIALS AND METHODS
The surgical pathology files of the Armed Forces Institute of Pathology (AFIP), Washington, D.C.; and of the University of Texas Southwestern Medical Center, the North Texas Veterans Affairs Medical Center, and Baylor Medical Center, Dallas, Texas, were searched for invasive papillary carcinomas of the extrahepatic bile ducts. Twenty-nine cases were found. Noninvasive and minimally invasive papillary carcinomas of the extrahepatic bile ducts and papillary carcinomas that arose in the ampulla of Vater were excluded. Papillary carcinomas in which only biopsy material was available and examples of biliary papillomatosis and villous adenoma were also excluded. Thirteen cases remained. Seven cases were accessioned in the AFIP files during a 31-year period between 1964 and 1995. Of the remaining six cases, two were retrieved from the University of Texas Southwestern Medical Center surgical pathology files, two from the Veterans Affairs North Texas Health Care Center, and two from the Pathology Department of Baylor Medical Center. These cases were accessioned from 1992 to 2001. Clinicopathologic data such as age, sex, site, tumor size, presence of lymph node and/or distant metastases, and follow-up were extracted from available pathology reports and clinical charts.
Routine hematoxylin and eosin-stained sections were available in all cases. The paraffin blocks and unstained slides were available in five and four tumors, respectively. Immunohistochemical studies were performed on an automated immunostainer (Ventana Bio Tek System, Tucson, AZ) using the standard avidin-biotin peroxidase complex technique and the heat-induced epitope retrieval buffer. The following primary antibodies were used: p53 (DO-7, 1:50 dilution, DAKO, Carpinteria, CA), MIB-1 (1:10 dilution, Bio Genex, San Ramon, CA), monoclonal carcinoembryonic antigen (CEA; 1:400 dilution, DAKO), cytokeratin 7 (1:40 dilution, DAKO), Dpc4 (MADR1 JV4 -1, 1:400 dilution, Santa Cruz Biotechnology, Santa Cruz, CA), neuronspecific enolase (BBS/VI-HI4, 1:4000, DAKO), synaptophysin (1:100, DAKO), and chromogranin (DAK-A3, 1:700, DAKO). Positive and negative controls were included with each run.
The SEER Program of the National Cancer Institute surveys the incidence and mortality of cancer in the United States. The SEER program covers 9.6% of the population. It includes five states (Connecticut, Iowa, New Mexico, Utah, and Hawaii) and four large metropolitan areas, including Detroit, Michigan; the San Francisco-Oakland Bay area, California; Atlanta, Georgia; and Seattle, Washington. For this study, data were taken from 1975 to 1998. The histologic slides were not reviewed. The diagnosis was based on the pathology report submitted to the SEER program. Survival curves were calculated by the Kaplan-Meier method.
RESULTS
The clinicopathologic data of the 13 patients are summarized in Table 1 . The male to female ratio was 1:1, and their ages ranged from 33 to 89 years (mean: 67 y; median: 69 y). None of the patients had associated risk factors such as ulcerative colitis or primary sclerosing cholangitis. Painless jaundice and abdominal pain were the most common complaints. The Whipple procedure was performed in 6 patients, common bile duct resection in 6, and right hepatic lobectomy in 1 patient. Follow-up was available in 10 patients. Three cases had a follow-up interval of Ͻ5 years. Six patients died of disease from 2 weeks to 2 years and 1 month after surgery. Four patients are alive with no evidence of disease from 4 months to 8 years and 8 months after surgery (40%).
Gross Findings
Five tumors were located in the distal portion, one in the mid portion, and six in the proximal portion of the common bile duct. One papillary carcinoma arose in the right hepatic duct. The tumors were polypoid or granular masses that projected into the bile duct lumen. Their sizes ranged from 0.8 to 3.5 cm (median, 1.5 cm).
Histologic Findings
The noninvasive component of all tumors was characterized by exophytic proliferation of complex papillary structures with or without gland formation (Fig. 1) . Papillary epithelial projections with fibrovascular cores of variable sizes were noted in all tumors. One neoplasm had a micropapillary architecture and was associated with extensive necrosis (Fig. 2) . Regarding cell phenotype, nine tumors were of biliary type and three of intestinal type. One tumor had a combined pattern of intestinal and biliary. The columnar biliary-type cells lining the papillae were well to moderately differentiated and showed few mitotic figures. The columnar intestinal-type cells were taller, pseudostratified, and with elongated nuclei. Rarely were goblet cells admixed with the columnar cells. Both biliary-type and intestinal-type epithelia contained little or no mucin. Focal extracellular mucin (10%) was identified in only one case.
The invasive component was comprised predominantly of infiltrative glands that invaded the full thickness of the ductal wall. Four tumors dedifferentiated. At the base of two papillary carcinomas, there was an undifferentiated component characterized by a diffuse proliferation of uniform small ovoid neoplastic cells with vesicular nuclei, visible nucleoli, and eosinophilic cytoplasm (Fig. 1) . Another tumor had cordlike or diffuse growth patterns and was composed of cells with scant cytoplasm, hyperchromatic nuclei, and ill-defined cell borders characteristic of small (oat) cell carcinoma ( Fig. 1) . In one additional case (Case 11), an anaplastic component characterized by pleomorphic giant cells was seen focally (Fig. 1) .
Three tumors showed an invasive papillary pattern similar to that of the noninvasive papillary component. Two tumors extended into the pancreas and three into the liver. Only one patient had lymph node metastasis at presentation.
Immunohistochemical Findings
Archival materials were available in 9 cases. The immunohistochemical results of these cases are summarized in Table 2 . Strong cytoplasmic staining to monoclonal CEA was noted focally in six cases (6/9). The undifferentiated components in three cases were negative for CEA. Cytokeratin 7 strongly labeled the neoplastic cells (9/9) in all nine cases with available archival materials, with the exception of the undifferentiated component in one case (Fig.  2) . Ki-67 immunolabeling were seen in nine of nine cases-high in eight cases (30 -100%) and moderate in one case (10%; Fig. 2 ). Carcinomas showing Ͼ30% nuclear p53 labeling were considered positive (4). Nuclear immunolabeling for p53 was noted in four of eight cases, with the exception of the undifferentiated component in one case (Fig. 2) . Loss of Dpc4 expression was noted in 5 of 8 cases (Fig. 2) . When present, Dpc4 positivity was noted in the cytoplasm with focal nuclear staining only. Nonneoplastic intramural glands, pancreatic epithelium, stromal fibroblasts, and lymphoid aggregates, all of which expressed Dpc4 with a moderate to strong intensity, served as internal positive controls.
The neoplastic cells of the small cell carcinoma component of one tumor showed immunoreactiv- ity for neuron-specific enolase and synaptophysin but were negative for chromogranin.
SEER Data
From 1975 to 1998, clinicopathologic data of 3534 invasive carcinomas of the extrahepatic bile duct carcinomas were reviewed. There were 174 invasive papillary carcinomas that comprised 4.9% of the total number of cases. Of these 174 tumors, 71 were confined to the ductal wall, 69 had regional node metastases, and 16 had distant metastases. Eighteen tumors were unstaged. The 5-and 10-year survival rates of invasive papillary carcinoma and adenocarcinoma of the extrahepatic bile ducts are summarized in Figure 3 . Invasive papillary carcinomas confined to the ductal wall have better 10-year relative survival (21%) rates than do invasive adenocarcinomas (12%; 
DISCUSSION
Papillary carcinomas represent 4 -5% of all malignant epithelial tumors of the extrahepatic bile ducts (1). The most common clinical presentation of the patients in this series was painless jaundice, followed by abdominal pain and weight loss, similar to that of patients with conventional adenocarcinomas. Papillary carcinomas of the extrahepatic bile ducts can be classified as invasive and noninvasive. This separation is important, because noninvasive and minimally invasive papillary carcinomas behave as in situ carcinomas (3). In contrast, in this small series of invasive papillary carcinoma, 60% of the patients died as a result of the tumor, but one patient has been followed for only 4 months. Most likely, with longer follow-up, the number of surviving patients would have decreased. Invasion of the full thickness of the ductal wall and beyond appears to be the most significant prognostic factor. Other factors probably play a role in the outcome of patients with papillary carcinomas of the extrahepatic bile ducts, such as the presence of undifferentiated carcinoma or small cell carcinoma at the base of the tumors, location, and lymph node metastasis. In our series, two of the three patients who had these high-grade undifferentiated or small cell carcinomas at the base of the papillary carcinomas died as a result of the tumors. The updated SEER data affirms that papillary carcinomas, even those with regional metastasis, have better prognosis than do other types of extrahepatic bile duct carcinomas. The 5-year and 10-year relative survival rates for 71 patients with invasive papillary carcinomas confined to the ductal wall are 28% and 21%, in comparison to 18% and 12% for those with conventional adenocarcinomas, respectively. Microscopically, the biliary type is more common than the intestinal type in both the noninvasive and invasive papillary carcinomas (3), but this cell phenotype appears to have no prognostic implications.
All of our tumors were strongly positive for CK7, thus confirming the previous observations of Rullier et al. (5) . This antibody lacks specificity but is useful in distinguishing extrahepatic bile duct carcinomas, intestinal type, from the exceedingly rare metastatic colorectal carcinomas, especially on biopsy specimens. Most extrahepatic bile duct carcinomas, as well as dysplastic lesions, express CEA (6) . Although CEA immunostain is not essential for diagnosis, it can be useful in delineating the extent of tumor infiltration and in distinguishing hyperplastic intramural glands from neoplastic ones, because normal glands are CEA negative. In addition, monitoring biliary CEA levels may be of importance in the management as well as in the detection of extrahepatic bile duct carcinomas (7) .
There was no significant difference in the staining for Ki-67, p53, or Dpc4 between the papillary component and the undifferentiated counterpart. However, lack of CEA expression is a common feature of the undifferentiated component. The p53 gene is one of the most commonly altered tumor suppressor genes in human cancer (8) . The p53 gene is located on the short arm of chromosome 17 (17p13), and it encodes for a nuclear phosphatase that plays an important role in cellular responses to DNA damage (9) . Expression of p53 protein has been reported in 38 -66% of invasive adenocarcinomas of the extrahepatic bile ducts (10, 11) . Fifty percent of the papillary tumors in this series express p53 protein, and this finding is accordance with previous published results. Although Argani et al. (12) and Diamantis et al. (13) found a higher percentage of distal extrahepatic bile duct carcinomas expressed p53 than the proximal ones; we were unable to confirm their findings. Although our results indicate that p53 is not a useful prognostic marker for extrahepatic bile duct carcinomas, other authors have shown an association between p53 expression and survival in extrahepatic bile duct carcinoma (11, 13, 14) . The reason for this discrepancy is unclear but may be due to the small number of tumors and to the inclusion of different histologic types of tumors in most series, or to different criteria for positive staining.
The Ki-67 antigen is expressed in active parts of the cell cycle (G1, S, G2, and M phases; 15). The correlation between MIB-1 and prognosis remains unconfirmed. Our study and that of Suto et al. (14) demonstrated no correlation between Ki-67 expression and survival. Larger series are needed to settle this issue.
Recent studies suggest that DPC4 (deleted in pancreatic carcinoma, locus 4; MADH4, SMAD4) gene, a tumor-suppressor gene on the long arm of chromosome 18, is frequently inactivated in pancreatic and bile duct carcinomas (12, 16 -19) . In contrast, inactivation of the DPC4 gene appears to be infrequent in other tumor types, such as carcinomas of the breast, lung, and colon (20) . Inactivation occurs by mutation in one DPC4 allele, coupled with loss of the other allele (loss of heterozygosity), or by deletion of both alleles (homozygous deletion; 9). The Dpc4 protein plays a critical role in transmitting growth-suppressive signals from transforming growth factor beta (21) . In a series of 32 biliary tract carcinomas, 16% had point mutation in the DPC4 gene by single-strand conformational analysis (16) . Rijiken et al. (22) studied 14 distal common bile duct carcinomas by comparative genomic hybridization and found that the most frequent site of loss was at the long arm of chromosome 18, which housed the DPC4 locus. Similarly, 60% of our invasive common bile duct papillary carcinomas showed loss of Dpc4 expression, thus confirming the findings of Argani et al. (12) that 55% of their distal bile duct carcinomas had loss of Dpc4 expression. We examined only one carcinoma that arose in the right hepatic duct and therefore are unable to confirm the lower loss of Dpc4 expression in these tumors.
We have shown that invasive papillary carcinomas have worse prognosis than noninvasive and minimally invasive papillary carcinomas but better prognosis than invasive adenocarcinomas arising in the extrahepatic bile ducts. Currently, the histologic type and the stage of disease are the most important prognostic factors in these invasive papillary tumors. Our findings suggest that there is no association between p53 and Ki-67 reactivity and Dpc4 lack of expression in these tumors and the survival of the patients.
Breast cytopathology is a field of diagnostic pathology that has developed most rapidly during the past 10 years. Fine needle aspiration of breast has its established role as a diagnostic tool. It is truly "visually pleasing and diagnostically satisfying," if everything is done right.
This book is a valuable addition to several already existing books and chapters dealing with breast cytopathology. It contains 16 chapters covering all aspects of breast cytology, including normal breast, non-neoplastic lesions, neoplastic lesions, male breast lesions, and nipple cytology. The prognostic markers are discussed in the last chapter. Cytological features in each category are described in detail. A summary of cytological features under each topic, along with the tables, are features to be found most useful by practicing pathologists. Pitfalls in each diagnostic category also are discussed. The histology and cytology illustrations are full and in color; most are of high quality. Only a few cytology pictures are suboptimal, partly due to the threedimensional nature of cytology specimens, which are difficult to photograph at high magnification.
I also liked the format. It has the size of a handbook. It should serve well to the residents, fellows, and pathologists in practice who deal with breast cytopathology.
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